Liquid Biopsy-Guided Lung Cancer Treatment
Liquid biopsy trial for lung cancer treatment. Phase II study using blood tests to guide targeted therapy for NSCLC mutations.
Phase II Trial of Liquid Biopsy-Guided Treatment Selection in Advanced Non-Small Cell Lung Cancer
Full Title
A phase II, single-arm study using circulating tumor DNA analysis to guide targeted therapy selection in patients with advanced non-small cell lung cancer and actionable mutations
Purpose
Instead of repeated tissue biopsies, this study uses blood tests (liquid biopsies) to find genetic changes in your lung cancer and choose the best targeted therapy. The blood test can detect cancer DNA and help doctors select treatments that target your cancer’s genetic weaknesses.
Primary Objectives
- Evaluate feasibility of liquid biopsy-guided treatment selection
- Assess objective response rate to liquid biopsy-selected targeted therapies
- Compare liquid biopsy results with tissue-based molecular testing
Diseases
- Lung Cancer
- Non-Small Cell Lung Cancer
- Advanced NSCLC with Targetable Mutations
Who Can Join this Trial
To participate in this study, you must meet ALL of the following criteria
- Have histologically confirmed advanced or metastatic non-small cell lung cancer
- Have a known actionable mutation detected by liquid biopsy (EGFR, ALK, ROS1, BRAF, MET, RET, or NTRK)
- Be either treatment-naïve for targeted therapy OR have progressed on previous targeted therapy
- Have at least one measurable lesion per RECIST v1.1 criteria
- ECOG performance status 0-2
- Age 18 years or older
- Life expectancy ≥12 weeks
- Adequate organ function including blood counts, liver, and kidney function
- No symptomatic brain metastases
Access Clinical Trials
Locations
CONTACT
📞 Call Now: 1-800-NEOVITA (1-800-636-8482)
🌐 Online Scheduling: Schedule Your Consultation
📧 Email: info@neovitaoncology.com